The number of percutaneous diagnostic and interventional procedures performed continues to increase. Despite the use of various methods to reduce the incidence of contrast-induced nephropathy, the development of renal failure remains a significant problem with iodinatedbased contrast agents. Patients with a baseline renal insufficiency are at considerably higher risk of permanent renal deterioration following exposure to iodinated contrast. The authors report a successful case of percutaneous stenting of the renal artery using a gadolinium-based contrast agent in a high-risk patient with renal insufficiency.
Get full access to this article
View all access options for this article.
References
1.
Waybill MM, Waybill PN: Contrast media-induced nephrotoxicity: Identification of patients at risk and algorithms for prevention. J Vasc Intervent Radiol12:3-9, 2001.
2.
Runback JH, Sacks D, Kent C: Guidelines for the reporting of renal artery revascularization in clinical trials. J Vasc and Intervent Radiol14:477-492, 2003.
3.
Rihal CS, Textor SC, Grill DE, et al: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation105:2259-2264, 2002.
4.
Soloman R, Werner C, Mann D, et al: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med331:1416-1420, 1994.
5.
Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate. JAMA291:2328-2334, 2004.
6.
Tepel M, Van Der Gies M, Schwarzfeld C, et al: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med343:180-184, 2000.
7.
Walker PD, Brokering KL, Theobald JC, et al: Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy. Pharmacotherapy23:1617-1626, 2003.
8.
Spinosa DJ, Matsumoto AH, Angle JF, et al: Safety of CO2 and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency. Am J Roentgenol176:1305-1311, 2001.
9.
Cigarroa RG, Lange RA, Williams RH, et al: Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med86:649-652, 1989.
10.
Rudnick MR, Goldfarb S, Wexler L, et al: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients, a randomized trial. The Iohexal study. Kidney Int47:254-261, 1995.
11.
Rofsky NM, Weinrab JC, Bosniak MA, et al: Renal lesion characterization with gadolinium-enhanced MR imaging: Efficacy and safety in patients with renal insufficiency. Radiology180:85-89, 1991.
12.
Furuichi S, Yasuda S, Arita Y, et al: Gadopentatate dimeglumine as a potential alternative contrast medium during percutaneous coronary intervention: A case report. Circ J68:972-973, 2004.
13.
Sarkis A, Badaoui G, Slaba S, et al: Gadolinium-based coronarography in a patient with renal failure: First clinical report. Cathet Cardiovasc Intervent54:68-69, 2001.
14.
Harb TS, Laird JR, Dieter RS: Renal artery stenting using gadodiamide arteriography in patients with baseline renal insufficiency. J Endovasc Ther11:553-559, 2004.
15.
Bokhari SW, Wen YH, Winters RJ: Gadolinium-based percutaneous coronary intervention in a patient with renal insufficiency. Cathet Cardiovasc Intervent58:358-361, 2003.
16.
Sarkis A, Badaoui G, Azar R, et al: Gadolinium-enhanced coronary angiography in patients with impaired renal function. Am J Cardiol91:974-975, 2003.
